{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:28:37Z","timestamp":1793179717251,"version":"4.5.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with the most commonly occurring of these being lymphoma, and is the most common cause of death in APDS patients. Management of APDS is complex and variable due to the heterogeneous nature of the disease and ranges from antimicrobial and immunosuppressant agents to haematopoetic stem cell transplantation. More recently, an increasing level of interest has been shown in the use of more targeted agents such as PI3K\u03b4-specific inhibitors. Here, we provide expert perspective on the suspected causality of a case of lymphoma observed in a 20-year-old female patient who was included in a clinical trial of leniolisib, a PI3K inhibitor.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1517543","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T01:13:53Z","timestamp":1736730833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Expert insights on Hodgkin\u2019s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment"],"prefix":"10.3389","volume":"15","author":[{"given":"Francesca","family":"Conti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Moratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: A large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: A cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u03b4 Syndrome: the european society for immunodeficiencies-activated phosphoinositide 3-kinase \u03b4 Syndrome registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0568-x","article-title":"Report of a chinese cohort with activated phosphoinositide 3-kinase \u03b4 Syndrome","volume":"38","author":"Wang","year":"2018","journal-title":"J Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1863982","article-title":"The first Iranian cohort of pediatric patients with activated phosphoinositide 3-kinase-\u03b4 (PI3K\u03b4) syndrome (APDS)","volume":"51","author":"Fekrvand","year":"2022","journal-title":"Immunol Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01218-4","article-title":"Activated phosphoinositide 3-kinase \u03b4 Syndrome: a large pediatric cohort from a single center in China","volume":"42","author":"Qiu","year":"2022","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.07.044","article-title":"Clinical manifestations and outcomes of activated phosphoinositide 3-kinase \u03b4 Syndrome from the USIDNET cohort","volume":"9","author":"Oh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103335","article-title":"Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an italian cohort of patients","volume":"9","author":"Tessarin","year":"2020","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","article-title":"Activated phosphoinositide 3-kinase \u03b4 syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity","volume":"152","author":"Maccari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12706","article-title":"Activating PI3K\u03b4 mutations in a cohort of 669 patients with primary immunodeficiency","volume":"183","author":"Elgizouli","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 Syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208567","article-title":"Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment","volume":"14","author":"Vanselow","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","article-title":"An updated review on activated PI3 kinase delta syndrome (APDS)","volume":"7","author":"Singh","year":"2020","journal-title":"Genes Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10238-023-01259-y","article-title":"Systematic review of mortality and survival rates for APDS","volume":"24","author":"Hanson","year":"2024","journal-title":"Clin Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.0190","article-title":"Clinical trials portfolio and regulatory history of idelalisib in indolent non-hodgkin lymphoma: A systematic review and meta-analysis","volume":"183","author":"Banerjee","year":"2023","journal-title":"JAMA Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0967","article-title":"PI3K inhibitors in hematology: When one door closes","volume":"30","author":"Sk\u00e5nland","year":"","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: Open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000326","article-title":"Seletalisib for activated PI3K\u03b4 Syndromes: open-label phase 1b and extension studies","volume":"205","author":"Diaz","year":"2020","journal-title":"J Immunol Baltim Md 1950"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2023.102201","article-title":"An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome","volume":"79","author":"Begg","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12061507","article-title":"Hodgkin lymphoma: biology and differential diagnostic problem","volume":"12","author":"Takahara","year":"2022","journal-title":"Diagnostics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell Malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"7Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaci.2018.04.030","article-title":"Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity","volume":"143","author":"Edwards","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature21406","article-title":"Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells","volume":"542","author":"Compagno","year":"2017","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-023-01626-0","article-title":"Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective","volume":"44","author":"Berglund","year":"2023","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180010","article-title":"Germline-activating mutations in PIK3CD compromise B cell development and function","volume":"215","author":"Avery","year":"2018","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702872","article-title":"Disorders related to PI3K\u03b4 Hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes","volume":"9","author":"Redenbaugh","year":"2021","journal-title":"Front Pediatr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2018.00237","article-title":"Herpesviruses in the activated phosphatidylinositol-3-kinase-\u03b4 Syndrome","author":"Cohen","year":"2018","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801911662","article-title":"Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients","volume":"49","author":"Pietersma","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0968-0004(97)01061-x","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03f5 Inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell Malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01835-1","article-title":"Report of the italian cohort with activated phosphoinositide 3-kinase \u03b4 syndrome in the target therapy era","author":"Barzaghi","year":"2025","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1517543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T01:13:55Z","timestamp":1736730835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1517543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2024.1517543"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1517543","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"article-number":"1517543"}}